Knee Arthritis OsteoarthritisKOA PRP ACSNCT07473232
Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS)
A study testing Autologous Platelet-Rich Plasma (PRP) and Conditioned serum (CS) in people with Knee Arthritis Osteoarthritis and Platelet Rich Plasma Injection, run by Pamukkale University at 1 site in Turkey (Türkiye).
Trial summary
The effects of single dose injection of platelet rich plasma or conditioned serum in the knee joint in patients with knee osteoarthritis will be compared Read more about this study
- Who is it for?
- Ages 40 to 80 years
- Conditions the study is for
- Knee Arthritis Osteoarthritis, Platelet Rich Plasma Injection, Conditioned Serum
- What is being tested?
- Autologous Platelet-Rich Plasma (PRP) and Conditioned serum (CS)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Apr 2026to 30 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of knee osteoarthritis according to ACR criteria at least 6 months ago.
- Being between grade 1-2 according to the Kellgren-Lawrence radiological classification.
- Not having had PRP injection in the last year.
- Knee pain ≥ 5 according to the visual pain scale.
Who cannot join
- Those with significant neurological or cardiovascular disorders.
- Those with active thrombovascular disease.
- Those with joint or skin infections.
- Those who have recently had an infectious disease.
- Those infected with Hepatitis B, C, and HIV.
- Those who have received intra-articular knee injections (hyaluronic acid, PRP, corticosteroids, and others) within the last year.
Show all 25Show fewer
- Those who use oral corticosteroids.
- Those who have used NSAIDs within the last week.
- Those who have used anti-platelet or anti-aggregant drugs within the last week.
- Those with coagulation disorders.
- Those with hemoglobin <10 g/dl and platelet count <100,000
- Those with cancer.
- Pregnant or breastfeeding women, drug addicts.
- Those scheduled for knee surgery or arthroscopy, or those who have undergone knee surgery or arthroscopy.
- Those with diseases causing secondary osteoarthritis:
- post-traumatic,
- congenital or developmental diseases
- Local diseases (leg length discrepancy, varus, valgus deformities, hypermobility syndromes, scoliosis)
- Generalized diseases (Bone dysplasias, Metabolic disorders (hemochromatosis, ochronosis, Gaucher disease, hemoglobinopathy, Ehlers-Danlos disease))
- Calcium storage diseases (calcium pyrophosphate storage disease, etc.)
- Other bone and joint diseases (avascular necrosis, rheumatoid arthritis, gouty arthritis, septic arthritis, Paget's disease, osteoporosis, osteochondritis)
- Other diseases
- Endocrine diseases (Diabetes mellitus, acromegaly, hypothyroidism, hyperthyroidism)
- Neuropathic arthropathy (Charcot joint)
- Other (Frost, Kashin-Beck disease, Caisson disease) -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Pamukkale University Hospital
Pamukkale, Denizli, 20070
GÜLİN FINDIKOĞLU, Professor, 05334227076, gulin_f@yahoo.com
About this study
The effects of single dose injection of platelet rich plasma or conditioned serum in the knee joint in patients with knee osteoarthritis will be compared
Read the detailed description
Patients with early grade bilateral knee osteoarthritis (Kellgren Lawrence grade 1 or 2) will be divided into 2 groups. One group of patients will be injected with single dose of autologous platelet rich plasma (PRP) in the knee joints. Other group of patients will be injected with eqiuvolume of autologous conditioned serum (CS) (also known as activated cytokine rich serum) in the knee joints. Patients' serum before injection, the treatment product (PRP and CS), patients serum 30 min after injection will be investigated for IL-1β, IL-1Ra, PDGF-BB, IGF-1, TGF-β and TNF-α. Patients' serum 1 week and 1 month after injection will be investigated for MMP-13, COMP by ELISA. Patients will also be investigated for visual pain scale, WOMAC (Western Ontorino and Mc Master) scale range of motion, ultrasonographic tibiofemoral cartilage thickness measurement and functional tests including the 30-second chair test, stair climb test, 40 meter fast paced walk test, timed up and go test, 6-minute walk test, and walking speed in the first week, first month and third month after injection.
- Being tested
- Autologous Platelet-Rich Plasma (PRP), Conditioned serum (CS)
- Keywords
- knee osteoarthritis, platelet rich plasma injection, conditioned serum injection, inflammation, cartilage
- Medical subject headings
- Osteoarthritis, Knee, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Autologous Platelet-Rich Plasma (PRP)Drug
Autologous Platelet-Rich Plasma (PRP) will be injected intra-articularly in patients with knee osteoarthritis
Conditioned serum (CS)Drug
Autologous conditionedserum (CS) will be injected intra-articularly in patients with knee osteoarthritis
| Study group | Role | What they receive |
|---|---|---|
| PRP group | Experimental | patients with knee osteoarthritis who will be injected with autologous PRP Receives: Drug: Autologous Platelet-Rich Plasma (PRP) |
| conditioned serum group | Experimental | patients with knee osteoarthritis who will be injected with autologous conditioned serum Receives: Drug: Conditioned serum (CS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual pain scale score
Visual pain scale score (min 0-max 10), higher scores indicate better results
Measured: Visual pain scale score (min 0-max 10) will be measured at the beginning ofthe study, 1 week, 1month and 3 months after the injection.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2026
- Study start1 Apr 2026
- Primary completion30 Aug 2026 (estimated)
- Study completion30 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Knee Arthritis OsteoarthritisStudies of the same condition, open and under way.
- More trials run by Pamukkale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- parallel, randomized, single blinded
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pamukkale University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, GULIN FINDIKOGLU, Pamukkale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07473232
- Sponsor's protocol ID
- E-60116787-020- 61586
- Other IDs
- 2025TIPF037
- Acronym
- KOA PRP ACS
- Status last verified
- Aug 2026
- First submitted
- 10 Mar 2026
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD will bw shared by the primary investigator upon personel contact.
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS)
- ClinicalTrials.gov ID
- NCT07473232
- Acronym / sponsor ID
- KOA PRP ACS / E-60116787-020- 61586
- Keywords
- knee osteoarthritis, platelet rich plasma injection, conditioned serum injection, inflammation, cartilage
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Pamukkale UniversityUniversity, hospital or other
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 30 Oct 2026 (estimated)
- First posted
- 16 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The effects of single dose injection of platelet rich plasma or conditioned serum in the knee joint in patients with knee osteoarthritis will be compared
Detailed description
Patients with early grade bilateral knee osteoarthritis (Kellgren Lawrence grade 1 or 2) will be divided into 2 groups. One group of patients will be injected with single dose of autologous platelet rich plasma (PRP) in the knee joints. Other group of patients will be injected with eqiuvolume of autologous conditioned serum (CS) (also known as activated cytokine rich serum) in the knee joints. Patients' serum before injection, the treatment product (PRP and CS), patients serum 30 min after injection will be investigated for IL-1β, IL-1Ra, PDGF-BB, IGF-1, TGF-β and TNF-α. Patients' serum 1 week and 1 month after injection will be investigated for MMP-13, COMP by ELISA. Patients will also be investigated for visual pain scale, WOMAC (Western Ontorino and Mc Master) scale range of motion, ultrasonographic tibiofemoral cartilage thickness measurement and functional tests including the 30-second chair test, stair climb test, 40 meter fast paced walk test, timed up and go test, 6-minute walk test, and walking speed in the first week, first month and third month after injection.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- parallel, randomized, single blinded
| Arm | Type | Receives |
|---|---|---|
| PRP group | Experimental | Drug: Autologous Platelet-Rich Plasma (PRP)patients with knee osteoarthritis who will be injected with autologous PRP |
| conditioned serum group | Experimental | Drug: Conditioned serum (CS)patients with knee osteoarthritis who will be injected with autologous conditioned serum |
Who may qualify
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosis of knee osteoarthritis according to ACR criteria at least 6 months ago.
- Being between grade 1-2 according to the Kellgren-Lawrence radiological classification.
- Not having had PRP injection in the last year.
- Knee pain ≥ 5 according to the visual pain scale.
Key exclusion criteria (25 listed)
- Those with significant neurological or cardiovascular disorders.
- Those with active thrombovascular disease.
- Those with joint or skin infections.
- Those who have recently had an infectious disease.
- Those infected with Hepatitis B, C, and HIV.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Autologous Platelet-Rich Plasma (PRP)Autologous Platelet-Rich Plasma (PRP) will be injected intra-articularly in patients with knee osteoarthritis | Drug | PRP group |
| Conditioned serum (CS)Autologous conditionedserum (CS) will be injected intra-articularly in patients with knee osteoarthritis | Drug | conditioned serum group |
Primary outcome
Visual pain scale score
Time frame: Visual pain scale score (min 0-max 10) will be measured at the beginning ofthe study, 1 week, 1month and 3 months after the injection.
Visual pain scale score (min 0-max 10), higher scores indicate better results
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2026.
- Individual participant dataSharing planned: Yes. IPD will bw shared by the primary investigator upon personel contact.
Related trials for Knee Arthritis Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Autologous Platelet-Rich Plasma (PRP) and Conditioned serum (CS) in people with Knee Arthritis Osteoarthritis and Platelet Rich Plasma Injection, run by Pamukkale University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact GÜLİN FINDIKOĞLU, Professor, MD, PhD (+905334227076, gulin_dr@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual pain scale score (time frame: Visual pain scale score (min 0-max 10) will be measured at the beginning ofthe study, 1 week, 1month and 3 months after the injection.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.